In Depth 19 Jul 2022 The biggest Asia-Pacific biotech investments in June 2022 The lab automation player MegaRobo stole the show in the Asia-Pacific region in June with a mega Series C round of $300 million. Oncology firms Doma Biopharmaceutical and Tessa Therapeutics also led the private biotech investment rankings. The Chinese lab automation developer MegaRobo was the decisive winner of June’s biotech investments in the Asia-Pacific region. […] July 19, 2022 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 19 Jul 2022 SINOVAC starts influenza vaccine trial in Chile Sinovac Biotech Ltd., a provider of biopharmaceutical products in China, has initiated a phase III clinical trial for SINOVAC’s inactivated quadrivalent influenza vaccine in Chile through a collaboration with the Pontificia Universidad Católica de Chile. SINOVAC said the results aim to provide scientific evidence to support its influenza vaccine immunogenicity and protection capacity. This clinical […] July 19, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
More News! 19 Jul 2022 Bayer Consumer Health launches microbiome research call to find new academic partners Campaign launch date: Monday, July 18, 2022. Bayer Consumer Health has launched a call through IN-PART’s Discover platform to find and partner with academic experts and research groups working on microbiome-targeting solutions for upper respiratory illnesses, nutrition and digestive health as well as topical delivery through the skin. The campaign aims to accelerate Bayer’s “Partnering […] July 19, 2022 - 3 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
News and Trends 19 Jul 2022 SK Bioscience signs deal with Novavax to manufacture COVID-19 vaccine South Korean company SK Bioscience has extended its partnership with Novavax, Inc., a U.S. biotechnology company specializing in next-generation vaccines, for the manufacturing and supply of Novavax COVID-19 vaccine targeting Omicron variants in prefilled syringes. SK Bioscience and Novavax signed an agreement for the technology transfer of Novavax proprietary COVID-19 variant antigen materials and manufacturing […] July 19, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 18 Jul 2022 FORTY51 Ventures closes $43M biotech fund and announces first investment FORTY51 Ventures has announced the closing of FORTY51 Ventures I, raising $43 million in its first close. FORTY51’s core strategy focuses on company formation and early-stage investments in biotech with geographic emphasis on Switzerland, France and Germany. FORTY51 Ventures will lead or co-lead early rounds (seed and series A) of its growing portfolio, which will […] July 18, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 18 Jul 2022 Positive results for drug combination used to treat rare blood cancer Exploratory analysis of anti-cancer drug, navitoclax, combined with ruxolitinib – a medication for the treatment of intermediate or high-risk myelofibrosis (MF) – has given positive results in a study. The data, announced by US biopharma company, AbbVie, comes from cohort 3 of a phase 2 REFINE study in Janus kinase (JAK) inhibitor naïve patients with […] July 18, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
More News! 18 Jul 2022 Purespring Therapeutics and SwanBio Therapeutics announce agreement for use of FunSel screening platform A licensing agreement for use of the FunSel screening platform has been announced by Purespring Therapeutics and SwanBio. Under the terms of the agreement, SwanBio will license the FunSel screening platform from Purespring to explore new targets for early-stage pipeline programs. SwanBio will have the option to develop any targets identified and to own and […] July 18, 2022 - 2 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 18 Jul 2022 Ginkgo Bioworks to collaborate with Sumitomo Chemical on animal-free personal care ingredient Cell programming company Ginkgo Bioworks has launched a new cell programming project as part of a broader collaboration with Japanese company Sumitomo Chemical Co., Ltd. Through the partnership, Sumitomo Chemical will leverage Ginkgo’s codebase and expertise in organism engineering to produce molecules in a sustainable way for products across a broad range of industries. The […] July 18, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 18 Jul 2022 Trial for drug targeting cancerous tumors begins in China A phase 1 trial to investigate a drug for treating people with advanced malignant neoplasms has begun in China. HUTCHMED announced the trial of anti-CD47 monoclonal antibody HMPL-A83 on Friday (July 15). It is the thirteenth innovative oncology drug candidate discovered in-house by HUTCHMED and it is the company’s second large molecule drug candidate to […] July 18, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 18 Jul 2022 Oxford Science Enterprises raises £250M Oxford Science Enterprises (OSE), the independent investment company created to found, fund and build transformational businesses via its partnership with the University of Oxford, has raised a further £250 million ($300 million) in funding. This brings the total amount raised by OSE to more than £850 million ($1 billion) since inception in 2015. These funds […] July 18, 2022 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 18 Jul 2022 First-ever Marketing Authorization Application for biosimilar targeting MS filed An international biotech, with headquarters in Amsterdam, has announced that the European Medicines Agency (EMA) has accepted the first-ever Marketing Authorization Application (MAA) for its biosimilar product. Polpharma Biologics, which is dedicated to the development of biosimilars, announced on Friday (July 15) that natalizumab, similar to Tysabri, which treats multiple sclerosis, has been accepted as […] July 18, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 18 Jul 2022 Enterome and Nestlé Health Science to work on food allergies and inflammatory bowel disease Enterome, a clinical stage biopharmaceutical company developing immunomodulatory drugs based on its bacterial Mimicry drug discovery platform, has signed a strategic R&D collaboration and license agreement with Nestlé Health Science targeting food allergies and inflammatory bowel disease (IBD). The collaboration aims to develop and commercialize Enterome’s lead EndoMimics pipeline candidate EB1010. EB1010 is a local […] July 18, 2022 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email